However, their NAT response evaluation seems particularly difficult compared to other breast cancer subtypes, possibly due to a reduced contrast uptake as a result of impaired angiogenesis of the tumor caused by HER2-targeted therapies [15,19,30,31,32,33,34]. This evidence concerns the gene ERBB2 and breast cancer.